Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 60/100

Failure Rate

9.1%

1 terminated/withdrawn out of 11 trials

Success Rate

75.0%

-11.5% vs industry average

Late-Stage Pipeline

1 trials in Phase 3/4

Results Transparency

0 of 3 completed trials have results

Key Signals

7 recruiting

Enrollment Performance

Analytics

N/A

4(80.0%)

Phase 4

1(20.0%)

5Total

N/A(4)

Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (11)

Showing 11 of 11 trials

NCT06955286Recruiting

Study on the Incidence of Adrenal Insufficiency After Surgery in Primary Aldosteronism Patients Concurrent With or Without Autonomous Cortisol Secretion

Role: lead

NCT06941116Recruiting

Steroids-Based Screening for Primary Aldosteronism

Role: lead

NCT06833437Not ApplicableRecruiting

68Ga-Pentixafor PET/CT Versus Adrenal Vein Sampling in Diagnosing Unilateral Subtype of Primary Aldosteronism Concurrent With Autonomous Cortisol Secretion (PREDICT)

Role: lead

NCT06635993Recruiting

Accuracy of 68Ga-Pentixafor PET/CT for Subtypting Diagnosis in Patients With Primary Aldosteronism Concurrent With Autonomous Cortisol Secretion

Role: lead

NCT06597630Recruiting

Pathological Type，Gene Mutation and Clinical Characteristics of Unilateral Primary Aldosteronism

Role: lead

NCT06457074Phase 4Recruiting

Finerenone for Patients With Primary Aldosteronism (FAIRY)

Role: lead

NCT06238232Not ApplicableRecruiting

Outcome of 68Ga-Pentixafor PET/CT Versus Adrenal Vein Sampling in Primary Aldosteronism